Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T)
Recruiting · NCT07215416 · Registry updated 2026-05-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Dyskinesias, Neurologic Manifestations, Nutritional and Metabolic Diseases, Primary Immunodeficiency Diseases, Spinocerebellar Ataxias, atactic disorder, non-human animal, ataxia telangiectasia, brain disorder, cardiovascular disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, hereditary disease, immune system disorder, inborn error of immunity, metabolic disease, nervous system disorder, neurocutaneous syndrome, telangiectasis, vascular disorder | Recruiting | Phase 1 / Phase 2 | 2026-05-28 | NCT07215416 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Timothy Yu | 1 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Boston Children's Hospital | Boston | United States | 343 |